Geison, Vicente, Calnan, Michael .W., Rech, Norberto, Leite, Silvana (2022) Pharmaceutical policies for gaining access to high-priced medicines: a comparative analysis between England and Brazil. Saúde em Debate, 46 (134). pp. 886-905. ISSN 0103-1104. (doi:10.1590/0103-1104202213422) (KAR id:94967)
PDF
Author's Accepted Manuscript
Language: English Restricted to Repository staff only |
|
Contact us about this Publication
|
![]() |
Microsoft Word (Word processing document)
Author's Accepted Manuscript
Language: English Restricted to Repository staff only |
|
Contact us about this Publication
|
![]() |
PDF
Publisher pdf
Language: English
This work is licensed under a Creative Commons Attribution 4.0 International License.
|
|
Download this file (PDF/378kB) |
Preview |
Request a format suitable for use with assistive technology e.g. a screenreader | |
Official URL: https://www.scielosp.org/article/sdeb/2022.v46n134... |
Abstract
Even though the National Health Service (NHS) and Unified Health System (SUS) are systems with similar universal principles, they can show different political measure patterns in the pharmaceutical field. The aim was to provide a comparative analysis of pharmaceutical policies highlighting strategies to guarantee sustainability and access to high-price medicines (HPM) between Brazil and England. An integrative literature review was performed in electronic databases between January 2009 and December 2019, supplemented by grey literature searched in governmental platforms (laws, decrees, ordinances, and resolutions). A total of 47 articles and 7 policies were selected for analysis, categorised according to the lifecycle of a pharmaceutical product framework. The results showed that both countries applied distinct policies to guarantee access to HPM, between them, policies to define prices and reimbursements, and actions to regulate the access and use of these medicines in the health systems. Also, these countries apply distinct policies to their own sustainability. While Brazil often uses partnerships for productive development, England uses a collaborative accelerated access program. In conclusion, despite similarities in the normative principles, these countries have been proposing and applying distinct policies to maintain access to HPM and ensure the sustainability of their health systems.
Item Type: | Article |
---|---|
DOI/Identification number: | 10.1590/0103-1104202213422 |
Uncontrolled keywords: | Health policy; Technology; High-Cost; Public health |
Subjects: |
H Social Sciences H Social Sciences > HV Social pathology. Social and public welfare R Medicine > RM Therapeutics. Pharmacology |
Divisions: | Divisions > Division for the Study of Law, Society and Social Justice > School of Social Policy, Sociology and Social Research |
Funders: | University of Kent (https://ror.org/00xkeyj56) |
Depositing User: | Michael Calnan |
Date Deposited: | 10 May 2022 15:40 UTC |
Last Modified: | 09 Jan 2024 23:56 UTC |
Resource URI: | https://kar.kent.ac.uk/id/eprint/94967 (The current URI for this page, for reference purposes) |
- Link to SensusAccess
- Export to:
- RefWorks
- EPrints3 XML
- BibTeX
- CSV
- Depositors only (login required):